Nightingale Health’s Board of Directors resolved on new stock option program

Nightingale Health Plc’s (“Nightingale Health”) Board of Directors has resolved to launch a new stock option program for Nightingale Health’s or its group companies’ employees or other key persons.

The purpose of Nightingale Health’s stock option programs is to bind the option holders to the company’s economic growth and the development of its market capitalization, as well as create a long-term relationship between the company and its option holders that benefits the company economically and operationally. The decision to launch the new stock option program was made based on the authorization granted by the Annual General Meeting held on 6 November 2025.

In accordance with the established practice for the company’s stock option rights, the right to subscribe for shares based on the new stock option program is earned upon reaching the following market capitalization steps, calculated based on the 45-day volume weighted average purchase price: EUR 500 million, 750 million, 1,000 million, 1,250 million and 1,500 million.

Each option right entitles the option holder to subscribe for one Series B share. The subscription price of each share is EUR 2.50 per share.

The total number of stock option rights that can be issued under the new stock option programs is 1,500,000, entitling holders to subscribe for a maximum of 1,500,000 Series B shares. 

The share subscription period for the stock option program ends on 31 May 2036.